Comparison of the Effectiveness of Oral Lactase Enzyme and Lactose Free Formula

NCT ID: NCT06827405

Last Updated: 2025-02-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-06-01

Study Completion Date

2024-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aimed to fill the gaps by comparing the effectiveness of oral lactase enzyme and lactose free formula in the management of secondary lactose intolerance in persistent and severe persistent diarrhea.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Although it is well understood that oral lactase enzyme can play a pivotal role in hastening recovery due to secondary lactose intolerance in persistent diarrhea, there is limited local data available in this regard. If exogenous oral lactase enzyme is found to be more effective, it would help children receive uninterrupted milk and milk-based diet during the diarrheal episode, as the former would aid digestion and absorption of lactose, thus providing the necessary nutrients especially (calcium) and vitamins so vital in this period of rapid growth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Secondary Lactose Intolerance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lactase enzyme group

In this group, 5 drops of lactase enzyme (200 units lactase/drop)/ounce of milk, was added 5-30 minutes before feeding.

Group Type EXPERIMENTAL

Lactase enzyme

Intervention Type DIETARY_SUPPLEMENT

Patients were given 5 drops of lactase enzyme (200 units lactase/drop)/ounce of milk, 5-30 minutes before feeding

Lactose-free formula feed group

In this group, lactose-free formula milk/diet was advised.

Group Type EXPERIMENTAL

Lactose-free formula feed

Intervention Type DIETARY_SUPPLEMENT

Patients were advised lactose-free formula milk/diet.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lactase enzyme

Patients were given 5 drops of lactase enzyme (200 units lactase/drop)/ounce of milk, 5-30 minutes before feeding

Intervention Type DIETARY_SUPPLEMENT

Lactose-free formula feed

Patients were advised lactose-free formula milk/diet.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Both genders
* Aged 6-24 months
* Presented with persistent or severe persistent diarrhea due to secondary lactose intolerance
* Patients on formula or mixed feeding, or formula/cow/buffalo milk

Exclusion Criteria

* Severe acute malnutrition
* Hemodynamic instability (shock)
* Those on oral antibiotics or on excessive juices
* With conditions of malabsorptive states (celiac disease, protein losing enteropathy, or irritable bowel syndrome)
Minimum Eligible Age

6 Months

Maximum Eligible Age

24 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Muhammad Aamir Latif

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Muhammad Aamir Latif

Research Consultant

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Fatima Ghayas, FCPS

Role: PRINCIPAL_INVESTIGATOR

Hamdard University Hospital, Karachi

Heena Ghayas, FCPS

Role: STUDY_DIRECTOR

Ziauddin University Karachi

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ziauddin University Hospital, Kemari

Karachi, Sindh, Pakistan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Pakistan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ZUHKARACHI

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.